Onco-Innovations Completes Standard Preparation for ONC010 API

Onco-Innovations Limited announced the successful completion of its analytical reference standard preparation program for A83B4C63, the active pharmaceutical ingredient (API) for its lead oncology program, ONC010. This milestone, achieved in collaboration with Dalton Pharma Services, is vital for future analytical testing. Reference standards are crucial in ensuring consistent evaluation of identity, purity, potency, and other key parameters in pharmaceutical development.

Dr. Islam Mohamed, Chief Medical Officer, emphasized that this achievement reinforces the company's quality systems for ONC010 and aids in reliable data generation for manufacturing and regulatory needs. The program's completion is part of recent advancements in the ONC010 development, including precursor scale-up and regulatory preparations.

CEO Thomas O'Shaughnessy noted this as a significant step, establishing qualified materials as foundational to pharmaceutical quality systems and supporting future clinical development. This achievement is part of Onco-Innovations' broader analytical strategy, which includes method qualification and quality control development.